secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001628280-24-035262
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharma Q2 revenue $9.9M, up 16% sequentially; adjusted earnings positive
--------------------------------------------------------------------------------

- Q2 net revenue $9.9M, 16% increase from Q1 2024; year-to-date $18.3M.
- Adjusted earnings $0.2M ($0.01/share), a $0.8M improvement vs prior Q1 period.
- Net loss $1.1M ($0.08/share) in Q2; year-to-date net loss $3.0M ($0.21/share).
- Product revenue: Kristalose $4.1M, Vibativ $2.5M, Sancuso $2.2M, Caldolor $0.8M in Q2.
- Cash $17.3M; $16.1M drawn on credit line; total assets $78.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828024035262/0001628280-24-035262-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828024035262/cpix-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-035262

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer